Research compounds Laboratory study Longevity research
Also discussed as: Epithalon
What it is and how it works
Epitalon is a short peptide studied in telomere-related experiments. The cited study examined telomerase activity in cultured human fetal fibroblasts. The word human describes the origin of the cells; it does not mean people received the peptide in a clinical trial.
Source for the mechanism context →A closer look at the cited evidence
Laboratory study
This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.
- Study or assessment
- Khavinson et al., 2003 — Epithalon in human cell culture
- Design
- Laboratory cell-culture experiment.
- Who or what was studied
- Human fetal fibroblast cultures, not human participants.
- What was observed
- Researchers observed telomerase-related changes and telomere elongation in the cultures.
- Limits of interpretation
- A cellular aging-related marker does not establish longer human life, better function, or clinical safety.
What the evidence means
A cellular marker cannot establish that a compound extends human life or improves healthy aging.
Approval and regulatory context
Not an FDA-approved longevity treatment.
Safety and uncertainty
Safety information for proposed routes is lacking.
What remains uncertain
Longevity claims require outcomes in living people over meaningful time periods. A plausible cellular hypothesis cannot establish those outcomes, nor can it reveal every consequence of changing a biological pathway.
These summaries are introductory and are not a complete account of the literature, adverse effects, contraindications, or interactions. Absence of a listed risk does not mean absence of risk. Different compounds, formulations, and routes cannot be treated as interchangeable.
Sources behind this overview
Read the source in its full context. Source links support the overview; they do not imply endorsement of this library by the source organization.